Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia

Area of Science:

• Hematology
• Oncology
• Clinical Prognostics

Background:

• Waldenström macroglobulinemia (WM) patient outcomes vary significantly.
• Existing prognostic models like the International Prognostic Scoring System may not fully capture current therapeutic landscapes.
• The frequent assessment of MYD88 mutations necessitates updated prognostic parameters.

Purpose of the Study:

• To re-evaluate prognostic parameters for Waldenström macroglobulinemia (WM) given advancements in therapies and diagnostic assessments.
• To develop and validate a new prognostic model for symptomatic WM patients.

Main Methods:

• A retrospective review of 889 treatment-naïve WM patients diagnosed between 1996 and 2017.
• Univariate analyses identified significant clinical predictors of overall survival (OS).
• A multivariable analysis using data from 341 patients derived a prognostic model, which was validated in an independent cohort of 335 patients.

Main Results:

• Age, elevated serum lactate dehydrogenase (LDH), and low serum albumin (<3.5 g/dL) were independently prognostic in the derivation cohort.
• A novel scoring system, the Modified Staging System for WM (MSS-WM), was developed using these parameters.
• The MSS-WM model stratified patients into four distinct risk groups with significantly different 5-year overall survival rates (93% low-risk to 55% high-risk in the derivation cohort; 93% to 57% in the validation cohort).

Conclusions:

• The Modified Staging System for WM (MSS-WM) is a simple and clinically useful prognostic tool.
• This externally validated model reliably risk-stratifies symptomatic WM patients into four prognostic groups.
• The MSS-WM aids in predicting overall survival and guiding clinical management decisions for WM patients.